SCHEMBL11044871

SCHEMBL11044871

CCOC(=N)C(O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
MMP8 P22894 1/20 0.44
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.42
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.40
PIN1 Q13526 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11041992 0.98 LMNA (0.44) LMNAMMP8POLBMAPK1TSHR
Hydrochloric Acid SCHEMBL11040198 0.82 PTGS1 (0.48) LMNAALDH1A1HPGD
Hydrochloric Acid SCHEMBL11043926 0.80 ALDH1A1 (0.39) LMNAGAAKDM4EALDH1A1TDP1
Hydrochloric Acid SCHEMBL11040499 0.79 CES2 (0.45) LMNA
Hydrochloric Acid SCHEMBL11040287 0.79 BRD4 (0.39) LMNAGAA
SCHEMBL4297584 0.78 MMP8 (0.57) LMNAMMP8POLBMAPK1TSHR
SCHEMBL27590464 0.78 MMP8 (0.57) LMNAMMP8POLBMAPK1TSHR
SCHEMBL3266292 0.78 MMP8 (0.57) LMNAMMP8POLBMAPK1TSHR
SCHEMBL279960 0.78 MMP8 (0.57) LMNAMMP8POLBMAPK1TSHR
SCHEMBL28929528 0.77 MMP8 (0.56) LMNAMMP8POLBMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253716-A1 AMINO-IMIDAZOLONES FOR THE INHIBITION OF BETA-SECRETASE WYETH (US) 2009-10-08 US disclosed
US-7563796-B2 Diphenylimidazopyrimidines as inhibitors of β-secretase WYETH (US) 2009-07-21 US disclosed
US-20090042912-A1 DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE WYETH (US) 2009-02-12 US disclosed
US-7456186-B2 Diphenylimidazopyrimidines as inhibitors of β-secretase WYETH (US) 2008-11-25 US disclosed
US-4448971-A Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1984-05-15 US disclosed
US-4407811-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1983-10-04 US disclosed
US-4399296-A TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES PFIZER INC. (US) 1983-08-16 US disclosed
US-4367234-A HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1983-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042912-A1 DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE BACE1, BACE2, APP LMNA 766/4885MMP8 1458/4885POLB 1880/4885
US-20090253716-A1 AMINO-IMIDAZOLONES FOR THE INHIBITION OF BETA-SECRETASE BACE1, BACE2, APP LMNA 818/4885MMP8 2553/4885POLB 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.